Tardive dyskinesia in geriatric patients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Aging Health

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/1745509X.2.5.833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in chinese schizophrenic patients

  2007cited by this paper
• Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.

  2006cited by this paper
• APOE2 allele increased in tardive dyskinesia

  2006cited by this paper
• Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial

  2006cited by this paper
• Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course

  2006cited by this paper
• Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

  2005cited by this paper
• Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events

  2005cited by this paper
• Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity.

  2005cited by this paper
• Tardive dystonia associated with ziprasidone.

  2005cited by this paper
• Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine

  2005cited by this paper
• An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.

  2005cited by this paper
• Antipsychotic Medications and Drug‐Induced Movement Disorders Other Than Parkinsonism: A Population‐Based Cohort Study in Older Adults

  2005cited by this paper
• Improvement in Tardive Dyskinesia with Aripiprazole Use

  2005cited by this paper
• Striatal binding of11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding

  2005cited by this paper
• Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

  2005cited by this paper
• The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review

  2005cited by this paper
• Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.

  2005cited by this paper
• Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia

  2005cited by this paper
• Treatment of severe tardive dystonia with pallidal deep brain stimulation

  2005cited by this paper
• Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 2: Incidence and Management Strategies in Patients with Schizophrenia

  2005cited by this paper
• Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.

  2005cited by this paper
• Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.

  2005cited by this paper
• Ziprasidone-induced tardive dyskinesia.

  2005cited by this paper
• Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.

  2005cited by this paper
• Neuroleptic‐induced acute and chronic akathisia: A clinical comparison

  2005cited by this paper
• Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia

  2005cited by this paper
• Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole

  2005cited by this paper
• Electron spin resonance spectroscopy reveals alpha‐phenyl‐N‐tert‐butylnitrone spin‐traps free radicals in rat striatum and prevents haloperidol‐induced vacuous chewing movements in the rat model of human tardive dyskinesia

  2004cited by this paper
• A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.

  2004cited by this paper
• Neuroleptic Drug Therapy in Older Adults Newly Admitted to Nursing Homes: Incidence, Dose, and Specialist Contact

  2004cited by this paper
• Contents of The American Journal of Psychiatry

  2004cited by this paper
• Tardive Dyskinesia Associated with Olanzapine in a Neuroleptic-Naive Patient with Schizophrenia

  2004cited by this paper
• Neuroleptic‐Induced Movement Disorders: Deconstructing Extrapyramidal Symptoms

  2004cited by this paper
• Prevalence of spontaneous oral dyskinesia in the elderly: A reappraisal

  2004cited by this paper
• Ziprasidone-related tardive dyskinesia.

  2004cited by this paper
• Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia

  2004cited by this paper
• A case of tardive dystonia successfully managed with quetiapine.

  2004cited by this paper
• Tardive dyskinesia in 2 patients treated with ziprasidone.

  2004cited by this paper
• The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

  2004cited by this paper
• Treatment-Emergent Tardive Dyskinesia With Quetiapine in Mood Disorders

  2003cited by this paper
• Oxidative Mechanisms and Tardive Dyskinesia

  2003cited by this paper
• Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene.

  2003cited by this paper
• Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.

  2003cited by this paper
• A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy.

  2003cited by this paper
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia.

  2003cited by this paper
• Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.

  2003cited by this paper
• Melatonin for the Treatment of Tardive Dyskinesia

  2003cited by this paper
• Tardive dyskinesia in elderly patients: an update.

  2003cited by this paper
• Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

  2003cited by this paper
• Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia.

  2003cited by this paper
• Aripiprazole-Induced Improvement in Tardive Dyskinesia

  2003cited by this paper
• Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

  2002cited by this paper
• Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

  2002cited by this paper
• Patient and caregiver characteristics and nursing home placement in patients with dementia.

  2002cited by this paper
• The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?

  2002cited by this paper
• Challenges to the use of nonpharmacologic interventions in nursing homes.

  2002cited by this paper
• Comparison of Risperidone with Olanzapine in Elderly Patients with Dementia and Psychosis

  2002cited by this paper
• Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia.

  2002cited by this paper
• General Summary

  2002cited by this paper
• Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association's Practice Research Network.

  2002cited by this paper
• The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal.

  2001cited by this paper
• Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

  2001cited by this paper
• Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.

  2001cited by this paper
• Amphetamine-Induced Dopamine Release and Post-Synaptic Specific Binding in Patients with Mild Tardive Dyskinesia

  2001cited by this paper
• Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.

  2001cited by this paper
• Vitamin B6 in the Treatment of Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Crossover Study

  2001cited by this paper
• Psychotropic drug use in elderly people with and without dementia

  2001cited by this paper
• Quetiapine-related tardive dyskinesia.

  2001cited by this paper
• Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

  2001cited by this paper
• Treatment of tardive dyskinesia with donepezil: a pilot study.

  2001cited by this paper
• Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?

  2001cited by this paper
• Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.

  2000cited by this paper
• Is melatonin treatment effective for tardive dyskinesia?

  2000cited by this paper
• Dopamine D3 receptor variant and tardive dyskinesia

  2000cited by this paper
• Improvement of tardive dyskinesia with risperidone: a case report.

  2000cited by this paper
• Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.

  2000cited by this paper
• Prevalence of spontaneous dyskinesia in schizophrenia.

  2000cited by this paper
• A long‐term, multicenter, open‐label study of risperidone in elderly patients with psychosis

  2000cited by this paper
• Tardive and idiopathic oromandibular dystonia: a clinical comparison

  2000cited by this paper
• Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

  2000cited by this paper
• Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility

  2000cited by this paper
• Tardive dyskinesia with quetiapine.

  1999cited by this paper
• Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy.

  1999cited by this paper
• Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

  1999cited by this paper
• The impact of OBRA '87 on psychiatric services in nursing homes. Joint testimony of the American Psychiatric Association and the American Association for Geriatric Psychiatry.

  1999cited by this paper
• Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.

  1999cited by this paper
• Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.

  1999cited by this paper
• Olanzapine and tardive dyskinesia

  1999cited by this paper
• Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.

  1999cited by this paper
• The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.

  1999cited by this paper
• Lower Incidence of Tardive Dyskinesia with Risperidone Compared with Haloperidol in Older Patients

  1999cited by this paper
• Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.

  1999cited by this paper
• Tardive dyskinesia in affective disorders.

  1999cited by this paper
• Tardive dyskinesia and atypical antipsychotic drugs.

  1999influential reference
• Vitamin E (α-Tocopherol) in the Treatment of Tardive Dyskinesia: A Statistical Meta-Analysis

  1998cited by this paper
• The natural history of tardive dystonia. A long-term follow-up study of 107 cases.

  1998cited by this paper
• Prospective study of tardive dyskinesia in the elderly: rates and risk factors.

  1998influential reference
• Tardive dyskinesia, clozapine, and treatment response.

  1998cited by this paper
• Drug-induced movement disorders.

  1998cited by this paper
• New Atypical Antipsychotics

  1998cited by this paper

• Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan

  2022cites this paper
• Identification and management of tardive dyskinesia: A case series and literature review

  2015cites this paper
• New and emerging treatments for symptomatic tardive dyskinesia

  2013influential citation